Orphan Therapeutics is a privately held drug development company. It was founded in 2003 with the purpose to develop and seek
regulatory approval for terlipressin for the treatment of Hepatorenal Syndrome
(HRS) type 1 in the US. Orphan Therapeutics licensed its development rights for
terlipressin to Ikaria, which was later acquired by Mallinckrodt.
Orphan Therapeutics continued to assist the Mallinckrodt
team through the FDA approval process, which was
successfully completed with the FDA
approval of Terlivaz (terlipressin) Injection to improve kidney
function in adults with hepatorenal syndrome in
September 2022.
